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This manuscript [1] describes the natural history of 15 children with late infantile CLN5 disease, that 
is, disease caused by mutations in CLN5 that begins between the ages of 2-7 yrs. This gene encodes a 
soluble lysosomal protein of unknown function, and is one of more than a dozen genes that cause 
diseases collectively known as the neuronal ceroid lipofuscinoses or Batten disease. Alongside the 
natural history, including some neurophysiology, the pathology and mutations in all patients were 
determined and expression of mutant protein was characterised for some, confirming absence of 
expressed protein as expected for some mutations. 
 
The first published description of CLN5 disease was in 1991 in Finnish patients [2], with the gene 
linked to chromosome 13 a few years later and then identified in 1998.  These children were carrying 
the same mutation and therefore had a rather homogenous disease course. This study is therefore 
of interest and value because it (1) provides a more detailed natural history of late infantile CLN5 
disease than previously available including survival data, bringing the total number of patients 
described in the literature to 40, (2) develops a new rating scale that could be used internationally to 
further extend this natural history data, (3) describes disease in patients with different mutations 
(nine different mutations in total) and nationalities, allowing genotype, phenotype correlation, and 
4) demonstrates the value of collaborative disease registries for rare diseases, as some of these 
patients are contained within one such international registry launched approximately 5 year ago 
through an EU FP7 project DEM-CHILD that has since expanded to include other countries.  
 
The specially devised rating scale periodically assesses changes in six functional domains over time, 
allowing the disease course to be established for each patient. The overall findings are significant 
because the presenting symptom and disease progression is not identical across all patients. For 
example, a decline in language abilities was the presenting symptom in less than half the patients. 
This study, nevertheless, clarifies that an early feature is impairment in language and learning, with 
onset of seizures and loss of vision being late occurrences. This is in contrast to other types of NCLs 
that begin in late infancy. Disease rating scales have long been used for the NCLs, the first in 2002 
for classic late infantile CLN2 disease [3], and later ones developed for CLN3 disease [4]. This rating 
scale could readily be adapted for the whole group of variant late infantile NCLs – CLN6, CLN7 and 
CLN8 diseases. This scale may also be useful for those carrying particularly mild mutations in CLN5, 
causing later onset of disease that may be much more protracted [5].  
 
The most interesting and perhaps unexpected finding of this study is that all the children progressed 
similarly from the onset with a moderate progression for the first 3 years. However, after 3 years, 
the rate of decline varied and this correlates with the genotype. Thus, use of a rating scale in CLN5 
disease can detect changes in the rate of decline from the ‘typical’ disease arising from complete 
loss of CLN5 function. This is important as it allows families and supporting agencies for health, 
social care and education, to plan future care for these children based on genotype and the 
associated predicted or emerging disease course, including life expectancy which for some patients 
may extend into their twenties. 
 
This data further provides the detailed natural history that is required as the basis of a control 
cohort in clinical trials. Thus, this will be an essential and invaluable resource as trial therapies 
emerge for CLN5 disease, to assess the efficacy of clinical trials. For this particular disease, these are 
likely to be based on enzyme replacement therapy, either direct, for one currently under 
development for CLN2 disease, or indirect via gene therapy. These therapies must be delivered as 
early in the disease course as possible to be most effective. For CLN5 disease, this will ideally be in 
the pre-symptomatic phase or as early in the initial 3-year slowly progressing phase as possible. For 
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